Neurospora Circadian Clock 3-variable model - sinusoidal light oscillations - PLM_52, version 1, SIMPLIFIED
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Neurospora Circadian Clock 3-variable model - sinusoidal light oscillations - PLM_52, version 1, SIMPLIFIED
应用场景：
创建时间：
2019-01-10
相关数据集
Effects of External Application of Traditional Chinese Medicine Hexue Tongbi Powder on Oxaliplatin-Induced Peripheral Neuropathy Among Patients With Colorectal Cancer: an Open-Label, Randomized Controlled Trial
Interventions: TCM group:Oxaliplatin-based chemotherapy, education disease related knowledge and He-Xue Tong-Bi Powder will be used;control group:Oxaliplatin-based chemotherapy and education disease r
NIAID Data Ecosystem70
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing
NIAID Data Ecosystem50
Outcome of Antiemetic Prophylaxis Among Pediatric Cancer Patients Receiving Moderate to Highly Emetogenic Chemotherapy at Pediatric Hemato-Oncology Ward of Tikur Anbessa Specialized Hospital: a Prospective observational study
The Data was Outcome of Antiemetic Prophylaxis Among Pediatric Cancer Patients Receiving Moderate to Highly Emetogenic Chemotherapy at Pediatric Hemato-Oncology Ward of Tikur Anbessa Specialized Hospi
DataCite Commons2024-06-18 更新40
A randomized phase III trial of palonosetron versus palonosetron plus dexamethasone (day1) for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy (HOPE-02)
Interventions: Palonosetron 0.75mg/body Dexamethasone 9.9mg/body Palonosetron 0.75mg/body Primary outcome(s): Complete response rate (overall period) Study Design: Parallel Randomized
NIAID Data Ecosystem60
Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010-2016: a longitudinal assessment
Background: Guidelines recommend primary prophylactic use of colony-stimulating factor (PP-CSF) when risk of febrile neutropenia (FN)—based on chemotherapy and patient risk factors—is high. Whether an
Taylor & Francis Group2020-02-20 更新40
